Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate

被引:43
|
作者
Lambert, Cecile [1 ]
Mathy-Hartert, Marianne [1 ]
Dubuc, Jean-Emile [2 ]
Montell, Eulalia [3 ]
Verges, Josep [3 ]
Munaut, Carine [4 ]
Noel, Agnes [4 ]
Henrotin, Yves [1 ]
机构
[1] CHU Sart Tilman, Inst Pathol, Bone & Cartilage Res Unit, B-4000 Liege, Belgium
[2] Clin Univ St Luc, Dept Orthopaed, B-1200 Brussels, Belgium
[3] Bioiberica SA, Dept Med Sci, Pharmacol Res Unit, Barcelona 08029, Spain
[4] Univ Liege, Inst Pathol, Lab Tumor & Dev Biol, GIGA Canc, B-4000 Liege, Belgium
关键词
ENDOTHELIAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; PLACEBO-CONTROLLED TRIALS; RHEUMATOID-ARTHRITIS; KNEE OSTEOARTHRITIS; EXPRESSION; METAANALYSIS; INTERLEUKIN-1-BETA; INFLAMMATION; GLUCOSAMINE;
D O I
10.1186/ar3771
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: This work aimed at comparing the production of inflammatory and pro-and anti-angiogenic factors by normal/reactive (N/R) or inflammatory (I) areas of the osteoarthritic synovial membrane. The effects of interleukin (IL)-1 beta and chondroitin sulfate (CS) on the expression of pro-and anti-angiogenic factors by synovial fibroblasts cells (SFC) were also studied. Methods: Biopsies from N/R or from I areas of osteoarthritic synovial membrane were collected at the time of surgery. The inflammatory status of the synovial membrane was characterized by the surgeon according to macroscopic criteria, including the synovial vascularization, the villi formation and the hypertrophic aspect of the tissue. We assessed the expression of CD45, von Willebrand factor and vascular endothelial growth factor (VEGF) antigen by immunohistochemistry in both N/R and I biopsies. The production of IL-6, -8, VEGF and thrombospondin (TSP)-1 by N/R or I synovial cells was quantified by ELISA. SFC were cultured in the absence or in the presence of IL-1 beta (1 ng/ml) and with or without CS (10, 50, 200 mu g/ml). Gene expression of pro-angiogenic factors (VEGF, basic fibroblast growth factor (bFGF), nerve growth factor (NGF), matrix metalloproteinase (MMP)-2 and angiopoietin (ang)-1) and anti-angiogenic factors (vascular endothelial growth inhibitor (VEGI), TSP-1 and -2) were determined by real time RT-PCR. Production of VEGI and TSP-1 was also estimated by ELISA. Results: Immunohistochemistry showed the increase of lymphocyte infiltration, vascular density and VEGF expression in I compared to N/R synovial biopsies. Synovial cells from I areas produced more IL-6, IL-8 and VEGF but less TSP-1 than cells isolated from N/R synovial biopsies. The expression of pro-angiogenic factors by SFC was stimulated by IL-1 beta. A time dependent regulation of the expression of anti-angiogenic factor genes was observed. IL-1 beta stimulated the expression of anti-angiogenic factor genes but inhibited it after 24 h. CS reversed the inhibitory effect of IL-1 beta on anti-angiogenic factors, VEGI and TSP-1. Conclusions: We demonstrated that synovial biopsies from I areas expressed a pro-angiogenic phenotype. IL-1 beta induced an imbalance between pro-and anti-angiogenic factors in SFC and CS tended to normalize this IL-1 beta-induced imbalance, providing a new possible mechanism of action of this drug.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] The efficacy of glucosamine and chondroitin sulfate in patients with painful knee osteoarthritis (OA): The glucosamine/chondroitin arthritis intervention trial
    Clegg, DO
    Reda, DJ
    Harris, CL
    Klein, MA
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S256 - S256
  • [32] Glucosamine and chondroitin sulfate in knee osteoarthritis: where now?
    Felson, David T.
    NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2006, 2 (07): : 356 - 357
  • [33] Symptom management in persons with osteoarthritis: Glucosamine and chondroitin sulfate
    Yoon, S
    Brunt, D
    Lowenthal, D
    Delafeunte, J
    GERONTOLOGIST, 2005, 45 : 333 - 333
  • [34] Symptom and structure modifying properties of chondroitin sulfate in Osteoarthritis
    Reginster, Jean-Yves
    Heraud, Florence
    Zegels, Brigitte
    Bruyere, Olivier
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2007, 7 (10) : 1051 - 1061
  • [35] Chondroitin sulfate synthase-2/chondroitin polymerizing factor: Characterization and impact on chondroitin sulfate biosynthesis
    Watanabe, Hideto
    Ogawa, Hiroyasu
    Shionyu, Masafumi
    Sugiura, Nobuo
    Hatano, Sonoko
    Nagai, Naoko
    Sato, Takashi
    Narimatsu, Hisashi
    Shimizu, Katsuji
    Kimata, Koji
    GLYCOBIOLOGY, 2012, 22 (11) : 1598 - 1599
  • [36] The Effect of Glucosamine and/or Chondroitin Sulfate on the Progression of Knee Osteoarthritis
    Sawitzke, Allen D.
    Shi, Helen
    Finco, Martha F.
    Dunlop, Dorothy D.
    Bingham, Clifton O., III
    Harris, Crystal L.
    Singer, Nora G.
    Bradley, John D.
    Silver, David
    Jackson, Christopher G.
    Lane, Nancy E.
    Oddis, Chester V.
    Wolfe, Fred
    Lisse, Jeffrey
    Furst, Daniel E.
    Reda, Domenic J.
    Moskowitz, Roland W.
    Williams, H. James
    Clegg, Daniel O.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (10): : 3183 - 3191
  • [37] The Efficacy of Glucosamine and Chondroitin Sulfate in Osteoarthritis Management: Review
    Alptekin, Derya Oezmen
    TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, 2009, 29 (06): : 1687 - 1694
  • [38] Role of chondroitin sulfate in the modulation of neuronal morphology
    Sotogaku, Naoki
    Tsutsui, Masato
    Nishi, Akinori
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2014, 124 : 179P - 179P
  • [39] Chondroitin sulfate from Scophthalmus maximus for treating osteoarthritis
    Ren, Zhenkun
    Ji, Yuanyuan
    Wang, Yi
    Dong, Liyuan
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2018, 108 : 1158 - 1164
  • [40] Glucosamine and chondroitin sulfate in knee osteoarthritis: where now?
    David T Felson
    Nature Clinical Practice Rheumatology, 2006, 2 : 356 - 357